Randomized Phase II/III Trial of Radiation with Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation with Weekly Cisplatin at 40 mg/m2 for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
HN009 is temporarily closed to accrual to the Non-OPC/p16-negative OPC Cohort, effective September 19, 2025 at 5pm ET.
HN009 is closed to accrual to the p16-positive OPC/CUP cohort, effective January 6, 2026.
